Moderna (NASDAQ: MRNA) shares delivered top returns to investors in the earlier days of the pandemic. This year, though, the stock is heading for a 30% loss, even though Moderna's coronavirus vaccine generates billions in revenue and profit. Looking ahead to 2023, you might be wondering whether Moderna's best days are in the past -- or if this vaccine maker still presents an opportunity.
Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.
Moderna (NASDAQ: MRNA) investors didn't need to have too much patience in the early days of the pandemic. The company brought its coronavirus vaccine candidate from drawing board to market in about nine months. Next year, though, Moderna investors may need to rely on their patience.